南方财经全媒体记者魏彤 广州报道 今年1一4月，广州全市新设外商投资企业2662家，同比增长14.8%；实际使用外资115.2亿元人民币，同 比增长1.4%，增速高于全国。 广州是名副其实的外资大市。过去5年，全市实际使用外资总额近2800亿元，在穗投资500强企业增至 362家、落地项目2025个；全市5.02万家外资企业，以1.8%的企业数占比，贡献了近三成进出口总值以 及近四成工业总产值和规上工业增加值。 在政策兑现机制上，广州市商务局按照"三减一优"（减环节、减时间、减材料、优服务）要求，优化提 升惠企政策"直达快享""免申即享"比例。公布政策兑现机会清单，明确标准、申报渠道、申报时间，邀 请超100名"政策体验官"为政策把脉问诊，提高政策预期，提振企业信心。 以政策促改革，以创新促发展，一个吸引外资的政策创新高地正在广州崛起。 今年年初，广州提出建设"12218"现代化产业体系，这既是广州应对全球产业变局的"战略密码"，也是 其通过新质生产力的"关键变量"实现城市新旧动能转换的关键路径。 1988年，宝洁以合资形式落户广州开发区，如今已发展为年产值超百亿元的智能制造标杆。宝洁在黄埔 区的生产基地和供 ...

"今年1-4月，广州全市新设外商投资企业2662家，同比增长14.8%""实际使用外资115.2亿元人民币，同 比增长1.4%，增速高于全国""过去5年，全市实际使用外资总额近2800亿元，在穗投资500强企业增至 362家、落地项目2025个""全市5.02万家外资企业以1.8%的企业数占比，贡献了近三成进出口总值以及 近四成工业总产值和规上工业增加值。"……5月20日，在广州市重点外资企业圆桌会上公布的一组组数 据显示出，在全球经济复苏承压背景下，广州这座"千年商都"再次彰显出强劲的经济韧性与活力，吸引 着跨国企业持续加码。 据悉，本次是广州连续第5年举办外资企业圆桌会，会上宝洁、安利、广汽丰田、林德、玛氏箭牌、太 古地产、中国欧盟商会华南分会、新世界、捷普电子、瑞穗银行、现代汽车氢燃料公司、百吉生物等12 家外资企业和机构代表畅谈投资规划，提出发展诉求和政策建议，商务、发改、科技、工信、市场监管 等部门负责人现场回应，并建立台账、全程督办，确保事事有着落、件件有回音。 政策创新筑巢引凤：从"亿元奖励"到"精准滴灌" 以政策促改革，以创新促发展，一个吸引外资的政策创新高地正在广州崛起。 "我们一年内获得了 ...

泰国财政部长：希望与美国生物技术公司、食品加工企业及健康产业展开合作。 ...

Group 1: Core Insights - The article highlights a significant shift in the health consumption behavior of young people, moving from passive to active consumption, and from selective to essential spending on health [1][2] - The "Z generation" is expected to become the dominant force in health consumption, driven by their increasing focus on health and wellness [2][3] Group 2: Trends in Health Consumption - Young consumers are increasingly favoring intelligent, convenient, personalized, and fashionable health products, indicating a new trend in health consumption [2][3] - The integration of technology in health products, such as smart health monitoring devices, is making health management a necessity rather than a luxury [3][4] Group 3: Cultural and Service Innovations - The fusion of traditional medicine with modern dietary trends is creating a new wave of health products that resonate with young consumers, such as herbal coffee and traditional health drinks [3][4] - Innovations in health services, including the use of virtual and augmented reality in fitness, are enhancing the convenience and accessibility of health-related activities for young people [4]

Core Viewpoint - The implementation of the "Health Integration into All Policies" initiative in Hainan Province aims to systematically consider health impacts in public policy, enhancing public health and health equity by 2030 [2][3] Group 1: Policy Framework - The "Implementation Plan" was issued on March 17, 2025, making it the first provincial-level document in China to promote health integration into all policies [2] - The plan outlines the establishment of two systems and two mechanisms: a leadership and technical support system, and a promotion and public participation mechanism [3] Group 2: Health Impact Assessment - By 2030, Hainan aims to fully implement health impact assessments for major public policies, significantly reducing health risks that threaten public health and safety [2][3] - Over 70% of counties in Hainan have established health impact assessment frameworks, with more than 30 assessments completed since pilot programs began in 2019 [3] Group 3: Special Actions - The province will conduct three special actions: major health risk intervention, proactive health collaboration, and health impact assessment actions to translate the theoretical framework into practical applications [3] - Specific initiatives will target youth mental health and childhood health promotion, addressing emerging health issues among these demographics [4] Group 4: Future Directions - Hainan plans to expand the coverage of health impact assessments and develop a comprehensive implementation model that extends health considerations beyond traditional disease prevention [4] - The province will also focus on weight management and health food industry development, promoting a supportive environment for healthy weight management and enhancing food industry transformation [4]

证券代码：002162 证券简称：悦心健康 公告编号：2025-036 上海悦心健康集团股份有限公司 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，不存在虚假 记载、误导性陈述或者重大遗漏。 上海悦心健康集团股份有限公司（以下简称"公司"）分别于2025年2月26日、 《关于公司回购股份方案的议案》，同意公司使用自有资金或自筹资金以集中竞价 交易的方式回购公司部分已发行的人民币普通股（A股）股票，回购股份将全部用于 注销并减少公司注册资本。本次回购总金额不低于人民币600万元（含）且不超过人 民币1,000万元（含），回购价格为不超过人民币5元/股（含），具体回购数量以回 购期限届满时实际回购的股份数量为准。回购股份的期限自股东大会审议通过回购 股份方案之日起不超过12个月。具体内容详见公司于2025年2月28日、2025年4月19 日披露在巨潮资讯网（www.cninfo.com.cn）上的《关于回购公司股份方案的公告》 （公告编号：2025-017）、《回购报告书》（公告编号：2025-033）。 已实施完毕。根据《上市公司股份回购规则》、《深圳证券交易所上市公司自律监管 指引第9号——回购股 ...

Group 1 - The core concept of "Chuan Xiaopu" is to provide a low-cost entrepreneurial model in the health sector, allowing individuals to start their own business with an investment of over 2000 yuan, while receiving health products and professional guidance [2] - The model addresses the employment challenges faced by university graduates in a competitive job market, offering a new avenue for economic independence and self-worth [2][3] - "Chuan Xiaopu" aligns with the growing consumer demand for health products and services, capitalizing on the increasing health awareness among the public [3] Group 2 - The entrepreneurial model not only helps individuals achieve self-value but also contributes to alleviating employment pressure by providing valuable labor to society [3] - The future expansion of "Chuan Xiaopu" is expected to attract more entrepreneurs, further addressing employment issues and invigorating the health industry [4] - The brand aims to transform from a health product provider to a lifestyle leader, promoting a comprehensive health management system for families [4]

Core Viewpoint - The company reported a net profit loss of approximately 724.52 million yuan for the year 2024, with no cash dividends or stock bonuses proposed for shareholders [33][87]. Company Overview - The company specializes in the research, production, and sales of patented innovative traditional Chinese medicine, while also expanding into biopharmaceuticals and the health industry [4][5]. - The company has developed a unique research model for innovative traditional Chinese medicine, focusing on major diseases and leveraging its strong scientific research capabilities [5][6]. Business Segments Traditional Chinese Medicine - The company holds 17 patented traditional Chinese medicines, covering eight major clinical disease systems, with leading positions in cardiovascular and respiratory disease treatments [5][19]. - Key products include Tongxinluo capsules, which treat coronary heart disease and cerebral infarction, and have received multiple national science and technology awards [8]. Biopharmaceuticals - The company has established a comprehensive development strategy for biopharmaceuticals, including international registration and global sales [6]. - It has received approvals for 13 ANDA products in the U.S. market and has submitted registration applications in 53 countries [6][20]. Health Industry - The company is actively developing health products based on traditional Chinese health theories, integrating modern technology [7]. - It has launched a series of health products aimed at various health needs, including heart health and anti-aging [7]. Financial Performance - The company achieved a total revenue of approximately 6.51 billion yuan in 2024, with a significant net loss [33]. - The proposed profit distribution plan for 2024 includes no cash dividends or stock bonuses, reflecting the company's current financial situation [87]. Market Position - The company ranks 7th among traditional Chinese medicine companies in China and 30th in the broader pharmaceutical industry [17]. - Despite a declining trend in the market for traditional Chinese medicine for cardiovascular diseases, the company has maintained a growing market share in oral formulations [19]. Product Performance - The market share of key products such as Tongxinluo capsules has increased from 13.64% in 2015 to 17.69% in the first half of 2024 [19]. - The company’s diabetes medication, Jinlida granules, saw its market share rise from 4.42% in 2015 to 16.20% in the first half of 2024 [20].

一、主要会计数据和财务指标 | 报告期指标 | 2025年一季报 | 2024年一季报 | 本年比上年增减(%) | 2023年一季报 | | --- | --- | --- | --- | --- | | 基本每股收益（元） | -0.0090 | -0.0141 | 36.17 | -0.0083 | | 每股净资产（元） | 0.89 | 1.06 | -16.04 | 1.08 | | 每股公积金(元) | 0.2 | 0.22 | -9.09 | 0.21 | | 每股未分配利润(元) | -0.47 | -0.31 | -51.61 | -0.36 | | 每股经营现金流(元) | - | - | - | - | | 营业收入(亿元) | 1.96 | 2.21 | -11.31 | 2.21 | | 净利润(亿元) | -0.08 | -0.13 | 38.46 | -0.08 | | 净资产收益率(%) | -1.01 | -1.32 | 23.48 | -0.77 | 数据四舍五入，查看更多财务数据>> 二、前10名无限售条件股东持股情况 前十大流通股东累计持有： 52789.84万股，累计 ...